醫藥股普遍捱沽 康龍化成、藥明系及樂普生物挫14%-44% 惟再鼎及永泰生物逆升15%-43%
恆指繼上周五由近半年低位大幅反彈逾500點後,今天長周末假後復市反覆續升59點或0.3%,上下波幅193點,總成交額719億元。
據外電報道,美國總統拜登即將簽署一項行政命令,以擴張美國生物製造業,降低對中國的依賴。醫藥股今天普遍逆市捱沽,尤其是藍籌藥明生物(02269.HK)最低見52.8元,創逾三個月低,現報54.15元,急挫19%,成交急增至8,270萬股,創逾五個月高;藥明康德(02359.HK)最低見69.3元,創2020年5月以來最低,現報69.8元,急挫15.6%,成交急增至1,153萬股,創七個月高;藥明巨諾-B(02126.HK)跌6.1%報4.02元。
上周一(5日)起獲深交所調入港股通名單、主要聚焦於腫瘤治療領域創新型生物製藥企業的樂普生物-B(02157.HK)繼上周五飆升2.8倍曾高見31.8元創紀錄高後,今天長周末假後復市回吐47%低見13.22元,現報14.1元,回吐近44%,交投維持活躍仍達270萬股。
領先全流程一體化醫藥研發服務平台--康龍化成(03759.HK)失守3月所創52周低位44.981元,最低見42.5元,現報42.5元,急跌14%,成交增至148萬股。
主要研發創新藥產品的開拓藥業-B(09939.HK)跌9.5%報11.74元,創逾五個月低。科濟藥業-B(02171.HK)及三葉草生物-B(02197.HK)跌5.5%及4.8%,報15.22元及2.8元。金斯瑞生物(01548.HK)低見20.75元,創逾三個月低,現報21.45元,跌7.7%。三生製藥(01530.HK)市前有四宗合計1.617億股以每股5.7元(上周五收市價)非自動對盤上板。該股終止三連升,今早低見5.27元,現報5.34元,回吐6.3%,成交增至1.77億股。
然而,內地細胞免疫治療生物醫藥公司永泰生物-B(06978.HK)價量齊呈異動,股價曾飆1.6倍至9元(受制牛熊線9.02元),現報5.01元,急漲43%,一向薄弱成交急增至1,895萬股。該公司上月尾宣布與開源醫療(300109.SZ)全資附屬上海新開源組合營拓腫瘤治療及診斷業務。
主要致力於為全球患者生產包括腫瘤、抗感染及自體免疫性疾病領域的創新藥物再鼎醫藥-B(09688.HK)連升第二天,最高見44元,創逾半年高,現報41.75元,續升15%,成交增至147萬股。威高股份(01066.HK)反覆續升2.3%報10.76元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.